Cargando…

Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?

BACKGROUND: Controlled anticoagulation is key to maintaining continuous blood filtration therapies. Objective: The study aimed to compare different blood sampling sites for activated partial thromboplastin time (aPTT) to evaluate anticoagulation with unfractionated heparin (UFH) in continuous renal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anton, Florin Ioan, Rus, Paul Adrian, Hagau, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430360/ https://www.ncbi.nlm.nih.gov/pubmed/32864461 http://dx.doi.org/10.2478/jccm-2020-0024

Ejemplares similares

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
por: Lardinois, Benjamin, et al.
Publicado: (2022)

Routine Lupus Anticoagulant Sensitive aPTT Testing Can Prevent Unnecessary LA Testing
por: Smit, Bob, et al.
Publicado: (2023)

An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant
por: Seethala, Srikanth, et al.
Publicado: (2013)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
por: Nguyen, Tung Phi, et al.
Publicado: (2021)

Patient with lupus anticoagulant caused aPTT prolongation corrected with prednisolone treatment and later anticoagulation treatment due to chronic atrial fibrillation
por: Frydrysiak, Marlena, et al.
Publicado: (2023)

Prevalent factor XII deficiency in cancer patients with isolated aPTT prolongation
por: Shin, Dong-Yeop, et al.
Publicado: (2015)

The First-Derivative Curve of the Coagulation Waveform Reveals the Cause of aPTT Prolongation
por: Shimomura, Daiki, et al.
Publicado: (2020)

The biphasic aPTT waveform to diagnose sepsis in patients with systemic inflammatory response syndrome
por: Hagg, D, et al.
Publicado: (2007)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections
por: Tan, Chuen Wen, et al.
Publicado: (2020)

Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients
por: Bachler, Mirjam, et al.
Publicado: (2019)

Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results?
por: Bronić, Ana, et al.
Publicado: (2021)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays
por: Thomas, Owain, et al.
Publicado: (2015)

Association of aPTT-Guided Anticoagulation Monitoring with Thromboembolic Events in Patients Receiving V-A ECMO Support: A Systematic Review and Meta-Analysis
por: Rajsic, Sasa, et al.
Publicado: (2023)

Runtime and aPTT predict venous thrombosis and thromboembolism in patients on extracorporeal membrane oxygenation: a retrospective analysis
por: Trudzinski, Franziska C., et al.
Publicado: (2016)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin
por: Ting, Clara, et al.
Publicado: (2018)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments
por: Davenport, Andrew
Publicado: (2012)

Impact of COVID-19 on monitoring of therapeutic unfractionated heparin
por: Adie, Sarah K., et al.
Publicado: (2020)

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin
por: Workman, Wesley E., et al.
Publicado: (2020)

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022)

Resistance to unfractionated heparin in the ICU: evaluation and management options
por: Levy, Jerrold H., et al.
Publicado: (2023)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Unfractionated heparin in acute chest syndrome: a pilot feasibility randomized controlled trial of unfractionated heparin vs. standard of care in acute chest syndrome
por: Seaman, Craig D., et al.
Publicado: (2020)

The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?
por: De Kesel, Pieter M.M., et al.
Publicado: (2019)

Administration of Direct Oral Anticoagulant Immediately after Unfractionated Heparin Bolus for the Treatment of Intermediate–High-Risk Pulmonary Thromboembolism
por: Hara, Nobuhiro, et al.
Publicado: (2020)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory
por: Kim, Moo Hyun, et al.
Publicado: (2014)

Aromatic Amines Exert Contrasting Effects on the Anticoagulant Effect of Acetaldehyde upon APTT
por: Hall, La'Teese, et al.
Publicado: (2014)

Serum albumin at resection predicts in-hospital death, while serum lactate and aPTT on the first postoperative day anticipate anastomotic leakage after Ivor-Lewis-esophagectomy
por: Scheufele, Florian, et al.
Publicado: (2022)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin
por: Maharaj, Satish, et al.
Publicado: (2018)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin
por: Kikkert, Wouter J., et al.
Publicado: (2015)

Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy
por: Zeljkovic, Ivan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_73olaqq07v42mgemigbnlbm357